Medicine 3.0: The ethical and scientific shift heart health needs
Most mornings you’ll find me in the water long before sunrise — swimming laps in the pool or, if I’m lucky, cutting through the cold silence of the ocean. It’s where I reset my breathing and my autonomic nervous system, and where I’m reminded how resilient the heart can be when supported — and how vulnerable it becomes without care.
Heart disease remains Australia’s leading cause of death, and yet so much of it is predictable and preventable. For years, cardiology has spent enormous resources treating disease once it announces itself — stents, ablations, surgeries, emergency admissions. But decades of data tell us the earliest signals appear years before symptoms. The real problem is not capability; it’s timing.
This is the rationale behind the emerging paradigm many now call Medicine 3.0. It is not defined by new machinery or new billing models. It is an ethical shift — a scientific and moral reorientation of what we prioritise, when we act, and how we partner with patients to protect long-term health.
From Medicine 1.0 to 3.0:
The evolution we can no longer ignore
As Peter Attia has articulated, the story of modern healthcare evolved in three major phases:
Medicine 1.0: Before science
Medicine 1.0 was the era before scientific thinking. Humans explained illness through whatever narratives they could muster, but nothing was testable, reproducible, or falsifiable. We weren’t wired for scientific reasoning; we were wired for stories.
Medicine 2.0: The scientific revolution
Medicine began to shift in the 17th century, accelerated by the acceptance of germ theory in the late 19th century and the emergence of randomised controlled trials — the crown jewel of evidence-based medicine. Medicine 2.0 excels at acute care: trauma, infections, heart attacks. It is why we survive car accidents, pneumonias and heart attacks that would have killed us a century ago.
But as Attia and others argue, Medicine 2.0 has plateaued. Acute crises are no longer the main threat to health span. Chronic diseases — cardiovascular disease, dementia, metabolic disorders and cancer now dominate morbidity and mortality. Treating them after they appear is simply too late.
Medicine 3.0: A proactive, personalised, preventative model
Medicine 3.0 builds on scientific rigor but shifts from evidence-based guidelines to evidence-informed personalisation. It emphasises:
- Early, targeted prevention
- Deep diagnostics, not superficial screening
- Personalised risk assessment based on genetics, imaging, biomarkers, and physiology
- Continuous partnership between patient and clinician
- Lifestyle as foundational, not optional
Where Medicine 2.0 asks, “How do we treat this disease?”, Medicine 3.0 asks, “How do we stop the disease decades before it starts?”
The ethical foundation of
Medicine 3.0
Ethics in this context is not about cost. It’s about acknowledging what we now know — and acting accordingly.
Medicine 3.0 says:
- Use the tools we already have to detect risk early.
- Treat heart risk before it becomes heart disease.
- Empower patients with understanding, not fear.
- Build systems for continuous health, not episodic care.
Ethical medicine is proactive, not reactive. It prevents suffering rather than managing its fallout. And the science makes this approach not only possible — but unavoidable.
The science is unequivocal: heart disease starts young, silent, and invisible
Atherosclerosis begins far earlier than symptoms do.1 Evidence from European Heart Journal reviews, long-term cohort studies, and the 2025 Lancet PURE study shows. 2
- Plaque formation begins silently, years before symptoms.
- 41% of major cardiac events occur in people labelled “low risk” by standard calculators.
- Normal blood tests do not guarantee normal arterial health.
We now have advanced tools that detect hidden disease:
- Coronary artery calcium (CAC) scans and CT imaging that directly visualises early plaque, and are one of the strongest predictors of 10-year risk.
- High-sensitivity troponin, detecting microscopic heart muscle stress.
- Detailed cholesterol analysis including Lipoprotein(a) and ApoB testing, identifying inherited risk missed by standard cholesterol tests.
- Polygenic risk scores, predicting lifetime cardiovascular risk decades in advance.
- Biomarkers of inflammation, now understood as a causal driver of atherosclerosis.
Medicine 3.0 recognises that “normal” often means “not examined deeply enough.”
Lifestyle is medicine — and the most accessible intervention we have
In traditional cardiology, lifestyle was “advice.” In Medicine 3.0, it is intervention.
We now know:
- Cardiorespiratory fitness is one of the strongest predictors of longevity.3
- Sedentary individuals who suddenly exercise vigorously increase their acute cardiac risk.4
- Sleep, psychological stress and well-being and nutrition significantly affect cardiovascular outcomes — even in normal-weight individuals.
Consistency — not intensity — protects the heart. Daily habits are medicine, and Medicine 3.0 puts them at the centre rather than the periphery.
Personalised prevention is no longer optional
Two people with identical cholesterol levels, blood pressure, or BMI may have completely different disease trajectories. Why?
- Lipoprotein(a) significantly increases the risk of heart attack and valve disease even with normal LDL.5
- Polygenic risk scores can identify individuals at four times higher lifetime risk.6
- Inflammation, as shown by the CANTOS trial, independently drives cardiovascular events.7
- Imaging can show plaque (the cause of most heart attacks) when blood tests still appear “normal.”8
Chronic risk factors behave like smoking: their damage is cumulative. We would never wait to tell someone to stop smoking until they were 50 with a 10% risk of cancer in the next 10 years, we tell them to stop immediately. For some reason we don’t treat lifetime elevations of cholesterol with this same intensity. The earlier we intervene, the larger the lifetime benefit. Managing elevated cholesterol for 40 years can reduce heart attack risk by up to 90%.9
This is prevention at its most powerful.
Technology and digital cardiology: powerful tools, human-centered application
- AI-enhanced ECGs can detect subtle heart weakness far earlier than traditional imaging.10
- Remote heart failure monitoring reduces hospitalisations by up to 30%.11
- Wearables and home diagnostics provide continuous physiological insights.
- Telehealth and personalised platforms make prevention accessible beyond clinic walls.
What a prevention-first healthcare system could look like
A Medicine 3.0–aligned Australia would:
- Make Heart Health Checks as routine as dental visits.
- Treat lifestyle as core medicine, not soft advice.
- Personalise risk using genetics, imaging, biomarkers, and physiology.
- Normalise early detection, not because it’s cheaper, but because it saves lives.
- Build systems around people, not diseases — prevention is continuous.
This shift would extend not just survival, but healthspan — the years lived with vitality, not frailty.
Challenges and opportunities
Medicine 3.0 faces real barriers:
- Cost and access to advanced diagnostics
- Scepticism toward moving beyond reactive care
- Privacy and data security concerns
- Variability in clinician training and adoption
Yet the potential benefits — fewer heart attacks, fewer strokes, fewer years lost — far outweigh the barriers. Advocates argue that delaying this shift is costlier, both ethically and economically.
A more evolved vision of healthcare
The heart thrives on steady, daily habits. So do healthcare systems.
Medicine 3.0 is a shift from:
- reacting to illness → cultivating health
- treating consequences → preventing causes
- episodic urgency → lifelong partnership
If we get this transition right, we will add years to life — but more importantly, life to years. And in my experience, both as a cardiologist and a leader in healthcare, that is the most powerful outcome we can deliver.
Find your local Advara HeartCare centre
See your GP promptly if you’re experiencing any symptoms of heart disease
About Advara HeartCare
Established in 2006, Advara HeartCare is Australia’s largest cardiology network, with 70 locations nationwide. Its team of more than 100 specialist cardiologists represents multiple subspecialties, providing coordinated care from acute intervention and imaging to prevention and rehabilitation. Through research, data and innovation, the company is committed to advancing cardiovascular care and improving heart health outcomes across Australia.
References
1
Ibanez B, Bundgaard H. REACT initiative: early cure of atherosclerosis through precision prevention. European Heart Journal. Sept 2025;46(33):3244–3246. Available at: REACT initiative
2
Yusuf S, Rangarajan S, Teo K, et al. PURE: burden of cardiovascular events by risk profile. The Lancet Global Health. Aug 2025;13(8):e1406–e1414. Available at: The burden of cardiovascular events
3
Singh B, Cadenas-Sanchez C, Fitzpatrick J, et al. Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique cohort studies. British Journal of Sports Medicine. 2024;58(10):556–565. Available at: Cardiorespiratory fitness is a strong and consistent predictor of morbidity
4
Kunutsor SK, Laukkanen JA. Physical activity, exercise and adverse cardiovascular outcomes. Expert Review of Cardiovascular Therapy. 2024. Available at: Physical activity, exercise and adverse cardiovascular outcomes
5
Tsimikas S, Marcovina S. Ancestry, Lipoprotein(a) and cardiovascular risk thresholds. Journal of the American College of Cardiology (JACC). 2022. Available at: Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
6
Inouye M et al. Genomic risk prediction of coronary artery disease in 480,000 adults. Journal of the American College of Cardiology (JACC). 2018;72(16):1883–1893. Available at: Genomic Risk Prediction of Coronary Artery Disease
7
Ridker PM et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). The New England Journal of Medicine (NEJM). Available at: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
8
Levy P, Tonkin A, Brown A, et al. Coronary artery calcium scoring – an evidence-based guide for primary care. Medical Journal of Australia. 2017;207(8):351–355. Available at: Cardiac Society of Australia and New Zealand position statement
9
Carrington MJ et al. CODE RED: Overturning Australia’s cholesterol complacency. May 2020, Baker Heart and Diabetes Institute, Melbourne, Australia
10
Attia Z et al. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nature Medicine. 2019. Available at: Screening for cardiac contractile dysfunction
11
Scholte NTB et al. Telemonitoring for heart failure: a meta-analysis. European Heart Journal. 2023. Available at: Telemonitoring for heart failure